Corporate Presentation
July 2014

Geron Analyst and Investor Meeting at ASH 2013
Presentation

 

2013 Annual Report
Download here

 
Corporate Profile
Geron is a clinical stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.
Recent NewsMore >>
DateTitle 
08/11/14Geron Corporation Reports Second Quarter 2014 Financial ResultsPrinter Friendly Version
08/05/14Geron to Assume Sponsorship of Myelofibrosis IST and INDPrinter Friendly Version
07/30/14Geron Announces Conference Call to Discuss Second Quarter 2014 Financial ResultsPrinter Friendly Version
Upcoming EventsMore >>
To be announced.
Stock Information
GERN (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$2.36
Change (%) Stock is Down 0.05 (2.07%)
Volume1,334,839
Data as of 08/20/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
  
Contact Information

Anna Krassowska, Ph.D.
Tel: 650-473-7765
E-mail: investor@geron.com or media@geron.com



RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts | Financial Tear Sheet Financial Tear Sheet
Close
Form content here please :)